Efficacy of infliximab therapy for refractory pouchitis

Efficacy of infliximab therapy for refractory pouchitis - Infliximab therapy for refractory pouchitis

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013370

Enrollment

Registered

2014-03-07

Start date

2013-06-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis, pouchitis

Interventions

infliximab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with refractory pouchitis after restorative proctocolectomy for ulcerative colitis

Exclusion criteria

Exclusion criteria: Patients with pre-existed malignancy, other infectious disease, heart failure, or infusion reaction for infliximab

Design outcomes

Primary

Measure	Time frame
Efficacy of infliximab treatment will be assessed with pouchitis disease activity index before and after treatment	—

Secondary

Measure	Time frame
Evaluate the association between dose of anti-TNF alpha before treatment and efficacy of treatment	—

Countries

Japan

Contacts

Public ContactMotoi Uchino

Hyogo college of medicine Inflammatory bowel disease center

uchino2s@hyo-med.ac.jp0798-45-6371

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026